Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?
G Garufi, L Carbognin, C Arcana, S Parola… - Cancer Treatment …, 2022 - Elsevier
Neoadjuvant chemotherapy (NACT) for breast cancer (BC) increases surgical and
conservative surgery chances. However, a significant proportion of patients will not be …
conservative surgery chances. However, a significant proportion of patients will not be …
[HTML][HTML] Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications
G Griguolo, M Bottosso, G Vernaci, F Miglietta… - Cancer Treatment …, 2022 - Elsevier
Over the last few years, the indication for chemotherapy use in HR+/HER2− early BC has
been significantly modified by the introduction of gene-expression profiling. In the adjuvant …
been significantly modified by the introduction of gene-expression profiling. In the adjuvant …
Breast cancer index identifies early-stage estrogen receptor–positive breast cancer patients at risk for early-and late-distant recurrence
Y Zhang, CA Schnabel, BE Schroeder, PL Jerevall… - Clinical Cancer …, 2013 - AACR
Purpose: Residual risk of relapse remains a substantial concern for patients with hormone
receptor–positive breast cancer, with approximately half of all disease recurrences occurring …
receptor–positive breast cancer, with approximately half of all disease recurrences occurring …
Using breast cancer gene expression signatures in clinical practice: unsolved issues, ongoing trials and future perspectives
R Varnier, C Sajous, S de Talhouet, C Smentek… - Cancers, 2021 - mdpi.com
Simple Summary Gene expression signatures were initially developed to take into account
tumor biology for adjuvant chemotherapy decision and have become a standard option in …
tumor biology for adjuvant chemotherapy decision and have become a standard option in …
Personalized medicine: present and future of breast cancer management
R Sabatier, A Gonçalves, F Bertucci - Critical reviews in oncology …, 2014 - Elsevier
Breast cancer is the first cause of cancer in women worldwide. Recent molecular analyses
have shown that it is not a single disease but a mixture of several diseases with different …
have shown that it is not a single disease but a mixture of several diseases with different …
[HTML][HTML] A narrative review of five multigenetic assays in breast cancer
C Zeng, J Zhang - Translational Cancer Research, 2022 - ncbi.nlm.nih.gov
Methods We conducted searches using the MeSH terms 'breast neoplasms' and 'genetic
testing'in the PubMed databases from root to 22 January 2021. We conducted an additional …
testing'in the PubMed databases from root to 22 January 2021. We conducted an additional …
Hormonal modulation of breast cancer gene expression: implications for intrinsic subtyping in premenopausal women
SM Bernhardt, P Dasari, D Walsh, AR Townsend… - Frontiers in …, 2016 - frontiersin.org
Clinics are increasingly adopting gene-expression profiling to diagnose breast cancer
subtype, providing an intrinsic, molecular portrait of the tumor. For example, the PAM50 …
subtype, providing an intrinsic, molecular portrait of the tumor. For example, the PAM50 …
Dual roles for immune metagenes in breast cancer prognosis and therapy prediction
A Alistar, JW Chou, S Nagalla, MA Black… - Genome medicine, 2014 - Springer
Background Neoadjuvant chemotherapy for breast cancer leads to considerable variability
in clinical responses, with only 10 to 20% of cases achieving complete pathologic responses …
in clinical responses, with only 10 to 20% of cases achieving complete pathologic responses …
Evaluation of the 12-gene molecular score and the 21-gene recurrence score as predictors of response to neo-adjuvant chemotherapy in estrogen receptor-positive …
H Soliman, S Wagner, DD Flake, M Robson… - Annals of surgical …, 2020 - Springer
Abstract Background Neo-adjuvant chemotherapy (NaCT) facilitates complete surgical
resection in locally advanced breast cancer. Due to its association with improved outcome …
resection in locally advanced breast cancer. Due to its association with improved outcome …
The story of the Magee equations: the ultimate in applied immunohistochemistry
R Bhargava, DJ Dabbs - Applied Immunohistochemistry & …, 2023 - journals.lww.com
Magee equations (MEs) are a set of multivariable models that were developed to estimate
the actual Oncotype DX (ODX) recurrence score in invasive breast cancer. The equations …
the actual Oncotype DX (ODX) recurrence score in invasive breast cancer. The equations …